Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)
Data

Cancers·Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)

DataAdvanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)

Back to the Advanced systemic mastocytosis hub →33 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview What it is Finding it Treating it Evidence The science Where you are Living with it What is coming Data

Data

Related pages

33

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

not linked directly; found by shared links

Cancer
Rosai-Dorfman-Destombes disease
Shares WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms, Cladribine, Driver mutation, Histopathology & immunohistochemistry and the tags subtype-page, haematologic.
Cancer
Erdheim-Chester disease
Shares WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms, Cladribine, Interferon alfa-2a/2b, Driver mutation and the tags subtype-page, haematologic.
Cancer
Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)
Shares Histopathology & immunohistochemistry and the tags subtype-page, haematologic.
Cancer
Relapsed and refractory classical Hodgkin lymphoma
Shares Allogeneic stem cell transplantation and the tags subtype-page, haematologic.
Cancer
Advanced-stage classical Hodgkin lymphoma (stage III to IV)
Shares the tags subtype-page, haematologic.
Cancer
Early-stage classical Hodgkin lymphoma (stage I to II)
Shares the tags subtype-page, haematologic.
Cancer
FLT3-mutated acute myeloid leukaemia
Shares Midostaurin, Secondary and therapy-related acute myeloid leukaemia, FLT3, Allogeneic stem cell transplantation and the tag subtype-page.
Cancer
PDGFRA D842V-mutant GIST
Shares Avapritinib, KIT, Liquid biopsy (ctDNA) and the tag subtype-page.

technologies

8

Allogeneic stem cell transplantation Comprehensive genomic profiling Cytokines & engineered cytokines Cytotoxic chemotherapy Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET)Histopathology & immunohistochemistry Liquid biopsy (ctDNA)Small-molecule kinase inhibitors

targets

3

drugs

6

ApprovedSmall-molecule kinase inhibitor (PDGFRA D842V / KIT)

Avapritinib · Ayvakit

ApprovedSmall-molecule hypomethylating agent (cytotoxic)

Azacitidine · Vidaza / Onureg (oral)

Phase 3small molecule

ApprovedPurine nucleoside analogue

Cladribine · Leustatin / Litak

HistoricRecombinant type I interferon (cytokine)

Interferon alfa-2a/2b · Roferon-A / Intron A / Sylatron

ApprovedSmall-molecule multikinase inhibitor (FLT3)

Midostaurin · Rydapt

companies

7

Bristol Myers Squibb Cogent Biosciences Johnson & Johnson Merck & Co. (MSD)Novartis Roche / Genentech Sanofi

terms

3

Cytopenias and myelosuppression Driver mutation Molecular response (MMR, MR4, treatment-free remission)

trials

2

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis EXPLORER

key papers

4

Efficacy and safety of midostaurin in advanced systemic mastocytosis EXPLORER: safety and efficacy of avapritinib in advanced systemic mastocytosis (phase 1)PATHFINDER: efficacy and safety of avapritinib in advanced systemic mastocytosis (phase 2 interim analysis)WHO classification of haematolymphoid tumours, fifth edition: myeloid and histiocytic neoplasms

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Key papers for the 39 rare-cancer subtype pages · diff · file

Wikipedia

Sources & links

Midostaurin in advanced SM (NEJM 2016)
NCCN Systemic Mastocytosis
Wikipedia

subtype-page haematologic

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Machine-readable versions of Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/advanced-systemic-mastocytosis/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id advanced-systemic-mastocytosis.

WebMCP tools registered on this page: onco_search, onco_get_entity.